Kimia Biosciences has been granted permission to manufacture new API for sale or for distribution namely Brivaracetam by Central Drugs Standard Control Organization, Ministry of Health & Family Welfare, FDA Bhawan, New Delhi, dated February 15, 2021 in FORM CT-22 under Drugs & Cosmetics Acts & Rules thereunder.
Kimia Biosciences is a pharmaceutical company and the state of the art manufacturing facility is manufacturing latest Bulk Drugs and intermediates (R&D based) for India and Overseas markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.90 |
| Dr. Reddys Lab | 1229.80 |
| Cipla | 1236.25 |
| Zydus Lifesciences | 944.20 |
| Lupin | 2313.15 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: